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Summary
Background Countries have agreed to reduce premature mortality from the four main non-communicable diseases 
(NCDs) by 25% from 2010 levels by 2025 (referred to as the 25 × 25 target). Countries also agreed on a set of global 
voluntary targets for selected NCD risk factors. Previous analyses have shown that achieving the risk factor targets can 
contribute substantially towards meeting the 25 × 25 mortality target at the global level. We estimated the contribution 
of achieving six of the globally agreed risk factor targets towards meeting the 25 × 25 mortality target by region.
Methods We estimated the eﬀ ect of achieving the targets for six risk factors (tobacco and alcohol use, salt intake, 
obesity, and raised blood pressure and glucose) on NCD mortality between 2010 and 2025. Our methods accounted 
for multicausality of NCDs and for the fact that, when risk factor exposure increases or decreases, the harmful or 
beneﬁ cial eﬀ ects on NCDs accumulate gradually. We used data for risk factor and mortality trends from systematic 
analyses of available country data. Relative risks for the eﬀ ects of individual and multiple risks, and for change in risk 
after decreases or increases in exposure, were from reanalyses and meta-analyses of epidemiological studies.
Findings The probability of dying between the ages 30 years and 70 years from the four main NCDs in 2010 ranged 
from 19% in the region of the Americas to 29% in southeast Asia for men, and from 13% in Europe to 21% in 
southeast Asia for women. If current trends continue, the probability of dying prematurely from the four main NCDs 
is projected to increase in the African region but decrease in the other ﬁ ve regions. If the risk factor targets are 
achieved, the 25 × 25 target will be surpassed in Europe in both men and women, and will be achieved in women (and 
almost achieved in men) in the western Paciﬁ c; the regions of the Americas, the eastern Mediterranean, and southeast 
Asia will approach the target; and the rising trend in Africa will be reversed. In most regions, a more ambitious 
approach to tobacco control (50% reduction relative to 2010 instead of the agreed 30%) will contribute the most to 
reducing premature NCD mortality among men, followed by addressing raised blood pressure and the agreed tobacco 
target. For women, the highest contributing risk factor towards the premature NCD mortality target will be raised 
blood pressure in every region except Europe and the Americas, where the ambitious (but not agreed) tobacco 
reduction would have the largest beneﬁ t.
Interpretation No WHO region will meet the 25 × 25 premature mortality target if current mortality trends continue. 
Achieving the agreed targets for the six risk factors will allow some regions to meet the 25 × 25 target and others to 
approach it. Meeting the 25 × 25 target in Africa needs other interventions, including those addressing infection-
related cancers and cardiovascular disease.
Funding UK Medical Research Council.
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Introduction
In response to the commitments made at the 2011 UN 
high-level meeting on non-communicable diseases 
(NCDs), countries have agreed to reduce premature 
mortality (deﬁ ned as the probability of dying between the 
ages of 30 years and 70 years) from the four main 
NCDs—cardiovascular diseases, cancers, chronic 
respiratory diseases, and diabetes—by 25% relative to 
2010 levels by 2025 (referred to as the 25 × 25 target). 
Voluntary global targets for seven NCD risk factors and 
for two health system interventions were also agreed 
in 2013.1
We have previously estimated the eﬀ ect of achieving 
the targets for six of the seven risk factors with global 
targets (tobacco and alcohol use, salt intake, obesity, and 
raised blood pressure and glucose) on global NCD 
mortality between 2010 and 2025.2 We found that, if the 
agreed risk factor targets are met, global premature 
mortality from the four main NCDs would decrease to 
levels that are close to the 25 × 25 target for men and 
there will also be substantial beneﬁ ts for women. There 
are striking regional variations in NCD mortality and in 
risk factor levels,3–10 which means that information at the 
regional level is needed for advocacy, planning, and 
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accountability. This study presents a regional-level 
analysis of the eﬀ ect of achieving the targets for six risk 
factors on premature mortality from NCDs between 2010 
and 2025.
Methods
Data sources
The methods and data sources have been described in 
detail in the earlier global publication.2 In brief, we used 
data for risk factor and mortality trends from systematic 
analyses of available country data, as detailed in the 
appendix. Relative risks for the eﬀ ects of individual and 
multiple risks, and for change in risk after decreases or 
increases in exposure, were from reanalyses and meta-
analyses of epidemiological studies, as detailed in the 
appendix.
Analytical approach
Our analytical approach was based on two epidemiological 
characteristics of NCDs. First, NCDs have many causes, 
the combined eﬀ ects of which lead to a particular disease 
rate in the population. Some of these causes are non-
modiﬁ able (eg, genetic determinants), unmeasured or 
poorly measured (eg, health-care quality or stress), or even 
unknown. Therefore, trends for a speciﬁ c NCD can be 
diﬀ erent from that of any single risk factor or small 
number of risk factors, depending on how the other 
determinants and medical treatment are changing. For 
example, cardiovascular disease mortality in high-income 
countries has decreased for decades, during which time 
some of its risk factors (eg, blood pressure, cholesterol, 
and, in some countries, smoking) have decreased and 
others (eg, obesity and smoking in other countries) have 
increased.11–13 To account for this characteristic, and 
consistent with the vast empirical evidence on proportional 
eﬀ ects, we analysed the eﬀ ects of risk factors on future 
NCD mortality as a proportion of projected death rates.
The second characteristic of NCDs is that, when 
exposure to one of its risk factors increases or decreases, 
the harmful or beneﬁ cial eﬀ ects on disease risk 
accumulate gradually.14–17 We accounted for this 
characteristic using relative risks (RRs) that were a 
function of time since exposure change. These two 
components of our approach can be incorporated in a 
time-based, population impact fraction (PIF) formula,18 
which estimates the proportion of disease-speciﬁ c deaths 
for years between 2010 and 2025 that would be avoided if 
risk factor exposures were reduced according to their 
targets. For each disease outcome causally associated 
with a risk factor, we calculated the time-based PIF for a 
given year (20XX) between 2010 and 2025 using the 
following formula:
where P20XX and P20XX are population distributions 
(which could be categorical or continuous) of risk factor 
exposure in year 20XX in the so-called business-as-usual 
scenario (BAU; ie, projections based on current trends 
with no additional action) and target scenario, 
respectively, and RR20XX is the RR in 20XX (see appendix 
of Kontis and colleagues2). The ﬁ rst term in the 
numerator is the weighted (by prevalence) disease risk if 
risk factors continue their current trend and the second 
term is the weighted disease risk if risk factor trends are 
changed according to their target. The risk factor 
exposure categories, denoted by j, account for both the 
level of exposure and for time since change in exposure. 
The RR for each exposure category in this equation 
depends on time since exposure change. This relation is 
an extension of the commonly used population 
attributable or impact fraction in which RRs are a 
function of exposure level but not of time.
We estimated the proportional reduction in mortality 
from each NCD if all six risk factor targets are achieved 
using the formula for the joint eﬀ ects of multiple risk 
factors, which accounts for multicausality and overlap of 
risk factors.19 When estimating the combined eﬀ ects of all 
six risk factors, we also accounted for the fact that raised 
blood pressure and glucose are mediators of the eﬀ ects of 
See Online for appendix
Research in context
Evidence before this study
We used a PubMed search done for a recent global analysis of 
NCD mortality and risk factor targets. The only modelling 
analysis of the role of risk factor targets in achieving the 
25 × 25 mortality target was done at the global level, with no 
regional information.
Added value of this study
This study analyses and presents the potential contributions of 
achieving the risk factor targets towards meeting the 
25 × 25 mortality target by region. The regions were those used 
by WHO, and a set of regions based on geography and 
economic development.
Implications of all the available evidence
No region is on-track to achieve the 25 × 25 mortality target 
under current trends. However, there are substantial 
diﬀ erences across regions, with marked reductions happening 
in the European region and Americas region contrasted 
with rising premature NCD mortality in Africa, where 
infection-related NCDs remain leading causes of premature 
death. Achieving the six risk factor targets will help all regions, 
but with noticeable diﬀ erences by region and sex in terms of 
which risks are most important, and how large the additional 
beneﬁ ts are.
PIF20XX
Σj jRR –20XX Σj jPˆ RR20XXj20XX=
Σj jP RR20XXj20XX
Pj20XX
ˆ
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body-mass index (BMI) on cardiovascular diseases. We 
obtained the direct and mediated eﬀ ects from a pooled 
analysis of 97 prospective cohorts.20 Similarly, the eﬀ ects 
of salt intake on cardiovascular diseases were analysed as 
mediated through blood pressure, to be able to use eﬀ ect 
sizes from randomised trials of salt reduction, most of 
which had blood pressure as an endpoint.21,22
We did all analyses separately by country, sex, 5-year age 
groups for people aged 30 years or older, and for each NCD 
causally associated with these six risk factors. We calculated 
regional results by aggregating age-speciﬁ c and sex-speciﬁ c 
number of deaths and population from each region’s 
constituent countries. Results are presented for WHO 
regions in the main paper, and for a set of alternative 
regions used in previous global analyses3,4 in the appendix. 
One of these alternative regions consisted of high-income 
countries in Asia Paciﬁ c (Japan, Brunei Darussalam, 
Singapore, and South Korea), Australia, New Zealand, 
North America, and western Europe. The other countries 
were divided based on their geography into central Asia 
and central and eastern Europe, Latin America and the 
Caribbean, Middle East and north Africa, east and southeast 
Asia and the Paciﬁ c, south Asia, and sub-Saharan Africa. 
We used age-speciﬁ c death rates to calculate the probability 
of dying from the four main NCDs between ages 30 years 
and 70 years in the absence of competing causes.
Risk factor scenarios
Our risk factor scenarios were based on the agreed global 
targets, with the addition of a more ambitious tobacco 
use target (50% relative reduction in prevalence instead 
of the agreed 30%; table 1). We calculated the contribution 
of risk factor targets based on how close achieving them 
would bring premature mortality to the 25 × 25 target 
compared with a baseline scenario. We used two types of 
baseline scenarios. First, when a risk factor had a rising 
trend in a country (eg, obesity and diabetes in most 
countries), we compared its target to the baseline of the 
rising trend. Second, when a risk factor already had a 
decreasing trend (eg, blood pressure and smoking in 
many high-income countries), we compared its target to 
a baseline of having kept the risk factor at its 2010 level. 
We used the second type of baseline because a decreasing 
risk factor trend means that progress is already being 
made towards the target in the BAU trend, and hence 
should be counted towards the estimated beneﬁ t of the 
risk factor target. The contribution of a risk factor 
towards achieving the mortality target can be greater 
than 100% when reducing the risk factor leads to a 
greater than 25% reduction in premature mortality.
Uncertainty estimation
Projections of mortality under the BAU trends did not 
include measures of uncertainty,24 although there is an 
active research agenda on projection methods.25,26 To 
quantify the uncertainty in epidemiological associations, 
we used a simulation approach, in which we used 
1000 draws from the uncertainty distributions of two of 
the inputs to the analysis—the RRs for the associations 
between risk factors and the proportion of excess relative 
risk (RR minus 1) remaining over time since exposure to 
a risk factor has stopped or been reduced—and repeated 
the calculations with these draws. The resulting 
uncertainty intervals are shown in the appendix and 
report the median of these draws as the central estimates 
and their 2·5th and 97·5th percentiles. Draws for 
diﬀ erent age groups were treated as correlated (ie, a 
higher RR in one age group implies a higher RR in other 
age groups); those for diﬀ erent disease outcomes were 
treated as uncorrelated. The uncertainty intervals should 
be treated as a lower bound to true uncertainty because 
they do not include the uncertainty of BAU trends.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. VK, CDM, GAS, and KDS collectively had full 
access to all the data in the study and the corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication.
Results
The probability of dying between ages 30 years and 70 years 
from the four main NCDs in 2010 varied substantially by 
region and was higher in men than women in every region 
(ﬁ gure 1). In men this probability ranged from 19% in the 
region of the Americas to 29% in southeast Asia; in women 
it ranged from 13% in Europe to 21% in southeast Asia. 
The number of deaths from the four main NCDs in people 
aged 30–69 years ranged between 0·7 million in the 
eastern Mediterranean and 3·3 million in southeast Asia 
(ﬁ gure 2). In people aged 70 years and older, the number of 
For a list of countries in each 
region see http://www.who.int/
about/regions/en/
Scenario
Tobacco use Agreed target: 30% relative reduction in 
prevalence; more ambitious target: 50% 
relative reduction in prevalence*
Harmful alcohol use 10% reduction in per capita alcohol 
consumption
Salt intake 30% reduction in mean population intake of 
salt and sodium
Obesity Halting the rise in the prevalence of obesity
Raised blood glucose and 
diabetes
Halting the rise in the prevalence of diabetes
Raised blood pressure 25% relative reduction in the prevalence of 
raised blood pressure
Calculations were done in three 5-year intervals for computational eﬃ  ciency. Risk 
factor exposure reductions were applied at the midpoint of each 5-year interval, 
which is about equivalent to ﬁ ve equal annual reductions. *For tobacco use, we 
estimated the eﬀ ects of meeting the global target as well as a more ambitious 
scenario, because eﬀ ective policies for reducing tobacco use have already been 
successfully implemented in a number of countries, making a 50% reduction a 
feasible target.9,23
Table 1: Risk factor scenarios
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Figure 1: Business-as-usual 
trends in the probability of 
dying from the four main 
non-communicable diseases 
(NCDs) between ages 
30 years and 70 years and 
trends if risk factors are 
reduced according to their 
targets for WHO regions
The results for the 
combination of all risk factors 
account for multicausality and 
for mediation as described in 
Methods. See the appendix for 
results by regions based on 
income and geography.
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deaths from the four main NCDs ranged from 0·7 million 
in Africa to 5·5 million in the western Paciﬁ c. The variation 
in the number of deaths is partly due to diﬀ erences in 
population size and age structure and partly due to 
diﬀ erences in death rates in each age group. The share of 
deaths from the four main NCDs that occurred in the 
younger age group (30–69 years) ranged between 30% in 
Europe and 56% in Africa.
Under the BAU scenario, there is a projected reduction 
in the probability of premature death from the four main 
NCDs between 2010 and 2025 in ﬁ ve of the six WHO 
regions, with the reduction ranging from 6·8% (eastern 
Mediterranean) to 20·3% (Europe) of the 2010 levels 
(ﬁ gure 1). The notable exception is Africa, where the 
probability of dying prematurely is projected to increase 
by 6·2% relative to 2010 if current trends continue with 
no additional action. Despite the decrease in the 
probabilities of death, population increase and ageing 
will lead to a projected rise in the number of deaths from 
the four NCDs between 2010 and 2025 in all six regions 
(ﬁ gure 2). The smallest projected increase in the number 
of NCD deaths in people aged 30 years and older is 
predicted to occur in Europe (about 200 000 additional 
deaths) and the greatest in southeast Asia (3·6 million 
additional deaths). When focusing only on those aged 
30–69 years, the BAU projected change in the number of 
deaths will range between a 100 000 reduction in Europe 
to a 1·4 million increase in southeast Asia.
Achieving the six risk factor targets will accelerate the 
decline in premature mortality in the ﬁ ve regions with 
projected BAU decline and will reverse the rising trend 
in Africa. As a result of the accelerated decline, the 
25 × 25 target will be surpassed in Europe in both men 
and women (26% reduction in premature NCD mortality 
relative to 2010) and achieved in women, and almost in 
men, in the western Paciﬁ c (25% and 23% reduction 
relative to 2010, respectively). The regions of the 
Americas, the eastern Mediterranean, and southeast Asia 
will approach the target (19–22% reduction in premature 
mortality relative to 2010). In Africa, achieving the six 
risk factor targets will lead to an 11% reduction in the 
probability of dying prematurely from the four main 
NCDs relative to 2010 in women and 9% in men. 
Achieving a more ambitious tobacco use reduction of 
50% relative to 2010 will lead to a further reduction in the 
probability of dying prematurely in all regions, and help 
the western Paciﬁ c surpass the 25 × 25 target. The 
additional beneﬁ t will be largest in Europe and the 
Americas, where the probability of dying prematurely 
will be reduced by a further 3% relative to 2010, above 
Figure 2: Number of deaths from the main non-communicable diseases (NCDs) among those aged 30–69 years and 70 years or older
(A) Number of deaths from the main NCDs among those aged 30–69 years and 70 years or older in 2010 and in 2025 at 2010 death rate under the business-as-usual 
scenario if the six risk factors are reduced according to their targets and if a more ambitious target on tobacco use is achieved for WHO regions. (B) Same information 
as (A) after subtracting the number of deaths in 2010. See the appendix for results by regions based on income and geography.
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and beyond the reduction under the agreed risk factor 
targets.
At the regional level, achieving the six risk factor targets 
will help delay or prevent between 2·2 million deaths in 
the eastern Mediterranean (7·2% of all deaths from the 
four main NCDs in people 30 years and older in this 
region over the analysis period) and 10·6 million deaths 
in the western Paciﬁ c (6·5%) from the four main NCDs 
between 2010 and 2025 (ﬁ gure 2). In people aged 
30–69 years, southeast Asia alone will account for nearly 
a third of the worldwide deaths delayed or prevented 
(5·1 million deaths), followed by 3·4 million (21% of 
worldwide deaths delayed or prevented in this age group) 
in the western Paciﬁ c. The largest number of deaths 
delayed in those aged 70 years or older will be in the 
western Paciﬁ c (7·2 million deaths; 34% of worldwide 
deaths delayed or prevented in this age group), followed 
by Europe (5·1 million deaths; 24%).
The ranking of individual risk factor targets in terms of 
their eﬀ ects on premature mortality was relatively similar 
across regions for men (ﬁ gure 3). Among the agreed 
targets, in most regions those for raised blood pressure 
(through both changes in diet and scaling up blood 
pressure treatment in primary care) and tobacco use will 
have the largest eﬀ ect in terms of reducing premature 
mortality among men; a more ambitious tobacco target 
of 50% reduction will have an even larger eﬀ ect than that 
of the raised blood pressure target and be the most 
eﬃ  cacious approach in all regions except Africa. In 
Africa, where tobacco use is less prevalent and smokers 
consume fewer cigarettes than in other regions, raised 
blood pressure is the most important risk among men. 
Achieving the targets on alcohol use, raised blood 
glucose, and obesity had the smallest eﬀ ects on 
premature mortality from the four main NCDs among 
men. Alcohol use, however, is a risk factor for a range of 
other NCDs, injuries, and infectious diseases, and in 
some former Soviet countries is the single leading risk 
factor for premature deaths from all causes combined 
among men.9,27 For women, raised blood pressure is the 
leading risk factor in every region except Europe and the 
Americas, where tobacco smoking among women is 
more common and where the ambitious (but not agreed) 
tobacco reduction would have the largest beneﬁ t. In three 
regions (Africa, Americas, and eastern Mediterranean) 
achieving the obesity target would have the second 
largest beneﬁ t for women.
Of the four main NCD groups, cardiovascular diseases 
were responsible for about half of NCD deaths in four 
regions, and about 40% of deaths in the Americas and 
the western Paciﬁ c, where more deaths were caused by 
cancers than cardiovascular diseases. Ischaemic heart 
disease was the leading NCD cause of dying prematurely 
in every region in 2010, except the western Paciﬁ c and 
Africa where ischaemic heart disease followed stroke 
(table 2). Ischaemic heart disease was followed by stroke 
in all regions except in the Americas where diabetes was 
the second largest NCD cause of premature death. 
Although premature cardiovascular disease mortality is 
projected to decline in all regions except in Africa, only 
Europe and the Americas will achieve a 25% reduction in 
premature cardiovascular disease mortality by 2025, 
relative to 2010, without further action. If the risk factor 
targets are achieved, however, all regions, including 
Africa, will meet or exceed a 25% reduction in premature 
cardiovascular disease mortality. Further, achieving the 
risk factor targets will lead to a reversal of the rise in 
diabetes mortality in four of ﬁ ve regions where premature 
mortality from diabetes is projected to rise.
Among cancers, the largest share of premature deaths 
was due to lung cancer, which was one of the ten most 
common NCDs in every region except Africa. Liver 
cancer ranked second in cancer deaths globally, and was 
in the top ten NCDs in Africa and the western Paciﬁ c. 
Liver cancer was followed by stomach cancer, breast 
cancer, and colorectal cancer, which were each in the 
leading ten NCDs in three to ﬁ ve regions. Under a BAU 
scenario, premature cancer mortality is projected to rise 
between 2010 and 2025 in three out of the six regions 
(Africa, eastern Mediterranean, and southeast Asia), a 
trend which will be reversed in the eastern Mediterranean 
and southeast Asia, but not in Africa, if the risk factor 
targets are met. The reversal in the eastern Mediterranean 
Figure 3: Ranking of the risk factor targets by region and by their 
contribution towards achieving the 25 × 25 mortality reduction target for 
WHO regions
A rank of 1 corresponds to the largest contribution. See appendix for results by 
regions based on income and geography.
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 Percentage of
deaths from the
main NCDs in people
aged 30–69 years
BAU 
reduction*
Reduction if risk 
factor targets are 
achieved*
Risk factor 
contribution 
towards the 25 × 25 
mortality target†
Number of deaths delayed or 
prevented between 2010 and 
2025†
2010 2025 30–69 years 70 years or older
African region—four main NCDs account for 29% of premature deaths in 2010 and 37% in 2025
Stroke 21·7% 19·8% –1% –30% >100% 610 000 480 000
Ischaemic heart disease 16·4% 15·3% +1% –24% 95% 380 000 310 000
Diabetes 9·7% 9·5% +4% –10% 51% 130 000 60 000
Cervix uteri cancer 4·5% 4·2% 0% 0% 3% 3000 <1000
Liver cancer 4·0% 4·7% +26% +20% 12% 30 000 1 000
Hypertensive heart disease 3·9% 3·7% +3% –39% >100% 150 000 170 000
Chronic obstructive 
pulmonary disease
3·8% 3·4% –4% –17% 66% 60 000 20 000
Breast cancer 3·8% 4·8% +35% +34% 1% 2000 <1000
Cardiomyopathy, 
myocarditis, and 
endocarditis
2·9% 2·8% +5% –11% 57% 50 000 30 000
Asthma 2·5% 2·5% +7% +5% 9% 8000 1000
Main four NCDs
Cardiovascular diseases 49·9% 46·7% +1% –25% 100% 1 300 000 1 000 000
Cancers 32·0% 35·8% +19% +14% 12% 160 000 30 000
Diabetes 9·7% 9·5% +4% –10% 51% 130 000 60 000
Chronic respiratory 
diseases
8·4% 8·0% +3% –6% 31% 70 000 20 000
Total 100% 100% +6% –10% 52% 1 600 000 1 100 000
Region of the Americas—four main NCDs account for 59% of premature deaths in 2010 and 62% in 2025
Ischaemic heart disease 20·4% 17·9% –25% –36% NA 630 000 830 000
Diabetes 9·5% 15·1% +32% –6% 68% 440 000 410 000
Stroke 9·2% 8·1% –25% –38% NA 340 000 440 000
Trachea, bronchus, and lung 
cancers
8·6% 7·7% –26% –16% NA 140 000 170 000
Chronic obstructive 
pulmonary disease
4·7% 4·2% –27% –20% NA 80 000 280 000
Breast cancer 4·1% 4·3% –7% –7% 2% 2000 <1000
Hypertensive heart disease 4·1% 3·4% –28% –42% NA 190 000 370 000
Colon and rectum cancers 3·6% 3·7% –13% –12% 12% 8000 10 000
Stomach cancer 2·5% 2·7% –7% –13% 43% 20 000 30 000
Pancreatic cancer 2·2% 2·4% –10% –7% 18% 10 000 20 000
Main four NCDs
Cancers 41·8% 42·4% –13% –10% 24% 240 000 290 000
Cardiovascular diseases 41·4% 36·2% –25% –35% NA 1 300 000 2 000 000
Diabetes 9·5% 15·1% +32% –6% 68% 440 000 410 000
Chronic respiratory 
diseases
7·3% 6·4% –28% –23% NA 90 000 320 000
Total 100% 100% –14% –20% 77% 2 100 000 3 000 000
Eastern Mediterranean region—four main NCDs account for 54% of premature deaths in 2010 and 59% in 2025
Ischaemic heart disease 26·1% 24·0% –15% –33% >100% 400 000 420 000
Stroke 14·2% 13·2% –15% –36% >100% 260 000 320 000
Chronic obstructive 
pulmonary disease
7·3% 7·1% –12% –23% 82% 70 000 60 000
Diabetes 5·2% 6·5% +12% –9% 62% 90 000 90 000
Breast cancer 4·4% 5·0% +11% +10% 0% <1000 <1000
Hypertensive heart disease 3·7% 3·5% –13% –40% >100% 90 000 130 000
(Table 2 continues on next page)
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 Percentage of
deaths from the
main NCDs in people
aged 30–69 years
BAU 
reduction*
Reduction if risk 
factor targets are 
achieved*
Risk factor 
contribution 
towards the 25 × 25 
mortality target†
Number of deaths delayed or 
prevented between 2010 and 
2025†
2010 2025 30–69 years 70 years or older
(Continued from previous page)
Trachea, bronchus, and lung 
cancers
2·7% 3·4% +19% –7% 60% 50 000 20 000
Rheumatic heart disease 2·2% 2·1% –12% –20% 66% 20 000 10 000
Cardiomyopathy, 
myocarditis, and 
endocarditis
2·2% 2·0% –13% –25% 97% 20 000 20 000
Stomach cancer 2·0% 2·2% –1% –11% 41% 10 000 7000
Main four NCDs
Cardiovascular diseases 51·8% 48·0% –14% –32% >100% 810 000 950 000
Cancers 31·8% 34·7% +4% –1% 17% 110 000 40 000
Chronic respiratory 
diseases
11·1% 10·8% –12% –20% 61% 80 000 70 000
Diabetes 5·2% 6·5% +12% –9% 62% 90 000 90 000
Total 100% 100% –7% –19% 72% 1 100 000 1 100 000
European region—four main NCDs account for 69% of premature deaths in 2010 and 69% in 2025
Ischaemic heart disease 30·0% 26·4% –30% –42% NA 1 300 000 1 900 000
Stroke 13·2% 12·1% –29% –43% NA 650 000 1 200 000
Trachea, bronchus, and lung 
cancers
10·1% 11·4% –13% –13% 55% 250 000 260 000
Colon and rectum cancers 4·3% 4·8% –14% –14% 18% 20 000 30 000
Breast cancer 3·9% 4·3% –11% –10% 3% 3000 1000
Stomach cancer 3·1% 3·5% –11% –19% 66% 50 000 60 000
Cardiomyopathy, 
myocarditis, and 
endocarditis
2·8% 2·1% –36% –42% NA 70 000 60 000
Chronic obstructive 
pulmonary disease
2·7% 2·5% –30% –32% NA 60 000 270 000
Pancreatic cancer 2·3% 2·7% –12% –12% 29% 20 000 30 000
Diabetes 2·0% 2·9% +9% –5% 47% 50 000 110 000
Main four NCDs
Cardiovascular diseases 52·2% 46·3% –30% –41% NA 2 300 000 4 200 000
Cancers 42·0% 47·3% –12% –12% 33% 450 000 470 000
Chronic respiratory 
diseases
3·9% 3·6% –30% –31% NA 70 000 310 000
Diabetes 2·0% 2·9% +9% –5% 47% 50 000 110 000
Total 100% 100% –20% –27% >100% 2 800 000 5 100 000
Southeast Asia region—four main NCDs account for 56% of premature deaths in 2010 and 63% in 2025
Ischaemic heart disease 24·0% 22·5% –15% –32% >100% 1 500 000 1 100 000
Stroke 17·6% 16·8% –15% –36% >100% 1 400 000 1 200 000
Chronic obstructive 
pulmonary disease
14·7% 14·0% –15% –28% >100% 660 000 550 000
Diabetes 6·1% 6·5% –6% –14% 55% 280 000 150 000
Hypertensive heart disease 3·1% 2·9% –16% –43% >100% 300 000 340 000
Asthma 3·1% 2·9% –16% –19% 38% 40 000 30 000
Mouth and oropharynx 
cancers
3·0% 3·3% +5% –10% 50% 150 000 30 000
Trachea, bronchus, and lung 
cancers
2·8% 4·0% +26% –7% 65% 320 000 130 000
Cervix uteri cancer 2·5% 2·5% –6% –7% 7% 10 000 1000
(Table 2 continues on next page)
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and southeast Asia will be due to the substantial beneﬁ ts 
of achieving risk factor targets on mortality from lung 
and stomach cancers. By contrast, there will be a limited 
eﬀ ect from achieving the risk factor targets on cervical 
cancer, which is among the most common NCDs in 
Africa and southeast Asia, and on cancer of the mouth 
and oropharynx, which is important in southeast Asia. 
This diversity of cancers, and of their risk factors and 
interventions, shows the need for a comprehensive 
cancer control strategy, including vaccination and 
treatment of infections that cause cancers, screening and 
treatment of precancerous lesions, reducing carcinogenic 
exposures in food and the occupational and community 
environments, and cancer treatment.28
Discussion
No WHO region will meet the 25 × 25 target if current 
mortality trends continue. However, if the targets for the 
six risk factors analysed here are achieved, both sexes in 
Europe and women in the western Paciﬁ c region will 
achieve the agreed target; with the exception of Africa, 
other regions will also approach this target. Meeting the 
mortality target in Africa needs a more diverse range of 
interventions than those related to the risk factor targets, 
including interventions for infection-related cancers and 
cardiovascular diseases. Tobacco use and raised blood 
pressure, both of which have eﬀ ective interventions and 
have been successfully reduced in many countries,5.23,29 
are important risk factors in most regions in terms of 
 Percentage of
deaths from the
main NCDs in people
aged 30–69 years
BAU 
reduction*
Reduction if risk 
factor targets are 
achieved*
Risk factor 
contribution 
towards the 25 × 25 
mortality target†
Number of deaths delayed or 
prevented between 2010 and 
2025†
2010 2025 30–69 years 70 years or older
(Continued from previous page)
Breast cancer 2·4% 2·7% +9% +8% 0% <1000 <1000
Main four NCDs
Cardiovascular diseases 50·9% 47·9% –14% –32% >100% 3 400 000 2 800 000
Cancers 24·3% 27·9% +7% –1% 26% 680 000 220 000
Chronic respiratory 
diseases
18·7% 17·7% –15% –26% >100% 720 000 590 000
Diabetes 6·1% 6·5% –6% –14% 55% 280 000 150 000
Total 100% 100% –9% –22% 80% 5 100 000 3 800 000
Western Paciﬁ c region—four main NCDs account for 74% of premature deaths in 2010 and 77% in 2025
Stroke 22·4% 19·3% –29% –45% NA 1 300 00 2 300 000
Ischaemic heart disease 13·2% 14·2% –11% –26% >100% 760 000 1 700 000
Trachea, bronchus, and lung 
cancers
10·0% 12·7% +7% –5% 42% 420 000 560 000
Liver cancer 9·8% 10·3% –6% –9% 15% 80 000 60 000
Stomach cancer 6·7% 6·9% –14% –23% 85% 180 000 230 000
Chronic obstructive 
pulmonary disease
5·8% 4·4% –40% –45% NA 120 000 1 100 000
Oesophagus cancer 3·8% 4·0% –13% –18% 44% 70 000 110 000
Diabetes 3·7% 4·8% +8% +2% 29% 100 000 110 000
Colon and rectum cancers 2·9% 3·0% –11% –12% 7% 8 000 20 000
Hypertensive heart disease 2·2% 1·8% –34% –55% NA 170 000 520 000
Main four NCDs
Cancers 46·3% 50·6% –5% –10% 29% 810 000 1 000 000
Cardiovascular diseases 42·7% 38·9% –24% –39% >100% 2 400 000 4 900 000
Chronic respiratory 
diseases
7·3% 5·6% –38% –42% NA 130 000 1 200 000
Diabetes 3·7% 4·8% +8% +2% 29% 100 000 110 000
Total 100% 100% –15% –24% 91% 3 400 000 7 200 000
See appendix for results by regions based on income and geography. *A negative number shows a decline and a positive number a rise in mortality. †Contributions of risk 
factors and number of deaths delayed or prevented are calculated compared with a situation of rising or stagnating risk factor trends as described in Methods; a contribution 
of 100% implies that achieving the risk factor targets will lead to exactly a 25% reduction in the probability of death from that disease; a contribution of more than 100% 
implies that if risk factor targets are achieved probability of death declines by more than 25%; NA refers to diseases and regions for which premature mortality is projected to 
decline by 25% or more under a business-as-usual (BAU) scenario; achieving the risk factor targets will further increase the decline in mortality but is not needed to achieve a 
25% reduction in mortality.
Table 2: Eﬀ ect of achieving risk factor targets on premature mortality from the ten leading causes of death among the four main non-communicable 
diseases (NCDs), by WHO region
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contributions towards achieving the 25 × 25 mortality 
target. A more ambitious, but feasible, target on tobacco 
use will further accelerate progress towards the 
25 × 25 target. Achieving the targets of halting the rise of 
obesity and raised blood glucose will be important 
among women, who tend to smoke less than men, in 
some regions.
The strengths of our study include providing an 
integrated analysis of how the globally agreed targets 
related to preventable risk factors will contribute towards 
achieving the 25 × 25 NCD mortality target at the regional 
level. This analysis will help identify regional risk factor 
and disease priorities and measure how much risk factor 
targets contribute towards NCD mortality reduction by 
region, and hence what additional actions and 
interventions might be needed to meet the 25 × 25 NCD 
target. This information, together with other region-
speciﬁ c factors such as the regulatory and health-care 
infrastructure that are needed for delivering 
interventions, will support planning and advocacy. Our 
analysis used data for risk factor exposure and mortality 
trends from systematic analyses that included up-to-date, 
comprehensive country-level data. Similarly, the eﬀ ects 
of risk factors on each NCD were from large 
epidemiological studies and meta-analyses. We 
accounted for multicausality and for the fact that beneﬁ ts 
of reducing risk factors for NCDs accumulate gradually.
Analyses of future trends and scenarios of population 
health like ours are also aﬀ ected by limitations. First, as 
with all estimations of future trends, there can be 
entirely unexpected changes in trends, which could 
worsen or improve population health. At the same time, 
analyses such as ours are needed to plan public health 
interventions and clinical programmes, but should be 
accompanied by preparedness for unexpected situations. 
Second, despite improvements in epidemiological 
surveillance, risk factor exposures and deaths in some 
countries and regions are aﬀ ected by data shortage or 
poor quality of data. For example, estimates of obesity 
and hypertension prevalence were based on 960 and 
786 country-years of data, respectively, but those of 
diabetes prevalence relied on 370 country-years of data. 
The increased global focus on NCD prevention and 
control should be accompanied by better country-level 
data on NCDs, especially on cause-speciﬁ c mortality, and 
their risk factors. Third, we used RRs from observational 
studies, which could have been aﬀ ected by residual 
confounding. To avoid overestimating the eﬀ ects of risk 
factors, we included only diseases with strong and 
probable evidence and used RRs from well-adjusted 
studies only. Fourth, there is an active research agenda 
aiming to improve the methods used for projecting 
mortality and risk factors into the future,24–26 which forms 
one of the essential inputs into our analysis. Fifth, we 
did not analyse physical inactivity because how much of 
its eﬀ ects are mediated through obesity and raised blood 
pressure and glucose has not been quantiﬁ ed, and 
because there are no consistent data for time trends. 
Although physical inactivity is an important NCD risk 
factor, mediation and multicausality mean that its 
exclusion is unlikely to have greatly changed the 
combined eﬀ ect of all risk factors together. Similarly, we 
did not analyse other forms of tobacco use because of 
the relative scarcity of data for exposure, which could 
have led to underestimation of the beneﬁ ts for some 
cancers in south Asia, where oral tobacco use is 
common. Finally, the base year in our analysis was 2010 
as indicated in the global monitoring framework 
endorsed by the World Health Assembly in May, 2013. 
Conceivably, changes in risk factor trends might have 
occurred since 2010 and should be taken into account in 
planning, including reversing unfavourable risk factor 
trends between 2010 and 2015 to accelerate progress in 
the remaining 10 years.
Of the two leading risk factors contributing towards the 
25 × 25 NCD target, there have been successes in tobacco 
control in a number of countries although many others 
are lagging behind in terms of implementing eﬀ ective 
tobacco control measures.9,23 Our results re-emphasise the 
important role of tobacco control as one of the most 
eﬀ ective ways of reducing the NCD burden in every 
region.30 Lower dietary salt and better diagnosis and 
treatment have contributed to reducing blood pressure in 
some high-income countries, which has in turn been one 
of the most important determinants of the decline in 
cardiovascular disease mortality.3,5,11–13 Locally applicable 
salt reduction or substitution strategies are urgently 
needed in low-income and middle-income countries, in 
which salt intake remains high.30 Higher coverage of blood 
pressure treatment requires strengthening of the primary 
care system and development and imple mentation of 
guidelines for use by primary care personnel.3,31
The two health system targets (treatment and 
counselling individuals with a cardiovascular disease risk 
of 30% or more including those with a previous 
cardiovascular event, and availability and aﬀ ordability of 
quality, safe, and eﬃ  cacious essential NCD drugs),1 also 
agreed in 2013, will contribute towards meeting the 
25 × 25 target in Africa and for additional health beneﬁ ts 
in other regions. These health systems targets will 
require expansion of universal health coverage and 
strengthening of primary care to facilitate risk-based 
prevention of cardiovascular diseases and enhance access 
to essential medicines.32 Drug therapy for cardiovascular 
risk factors also needs up-to-date risk prediction charts 
and simpliﬁ ed guidelines for use at the primary-care 
level.33,34 In addition to current targets, the important role 
of NCDs that are related to infections (cervical and liver 
cancers, and infection-related cardiovascular diseases 
such as cardiomyopathy, myocarditis, and endocarditis) 
show the continued need for prevention and early 
detection and treatment of infections as an important 
component of addressing the rising NCD burden, 
especially in Africa.11,35
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Debate and priority setting for action on NCDs is 
moving from global to regional and national levels. The 
July 2014 UN high-level meeting on the comprehensive 
review and assessment of the progress achieved in the 
prevention and control of NCDs reviewed progress since 
September, 2011. The meeting concluded that, although 
substantial progress has been made, the pace of progress 
has been insuﬃ  cient and highly uneven, and that 
continued and increased eﬀ orts are essential for achieving 
a world free of the avoidable burden of NCDs. The 
meeting emphasised the need to move from commitments 
to action, in particular developing a set of national targets 
to complement the globally agreed voluntary targets and 
taking actions to meet these targets.36–38 The country focus 
is particularly important because, even within regions, 
there are diﬀ erences in risk factor levels and contributions 
to NCD mortality and in strategies to reduce risk factors. 
For example, within the western Paciﬁ c region, tobacco 
followed by obesity are the most important risk factors in 
Australia, whereas in China, the largest contribution 
towards achieving the mortality target will come from 
achieving the targets for raised blood pressure. In the 
Americas, the ambitious tobacco target, followed by 
obesity, are the most important targets in the USA, 
whereas in Mexico the targets for raised glucose and 
obesity will lead to the largest reductions in premature 
mortality. Therefore, our analysis should be followed by 
extending to country-level analysis to inform and facilitate 
national target setting and monitoring.
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